Back to Search
Start Over
PAPP-A and IGFBP-4 fragment levels in patients with ST-elevation myocardial infarction treated with heparin and PCI.
- Source :
-
Clinical biochemistry [Clin Biochem] 2015 Mar; Vol. 48 (4-5), pp. 322-8. Date of Electronic Publication: 2014 Dec 06. - Publication Year :
- 2015
-
Abstract
- Objectives: Circulating levels of pregnancy-associated plasma protein-A (PAPP-A) predict outcome in patients with acute coronary syndrome (ACS). Unfortunately, administration of heparin to patients with ACS increases circulating PAPP-A, probably by a detachment of PAPP-A from cell surfaces, inducing a considerable bias when using PAPP-A as a biomarker. It remains unknown whether PAPP-A-derived N- and C-terminal fragments of insulin-like growth factor binding protein-4 (NT-IGFBP-4/CT-IGFBP-4) are acutely affected by the increase in PAPP-A.<br />Methods: We prospectively included 78 patients with ST-segment elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention (PCI). Prior to PCI, patients were injected with 10,000IU of unfractionated heparin (UFH). Blood samples were collected immediately before PCI, but after UFH-injection, immediately after PCI and on day 1 and day 2. Plasma IGFBP-4, CT-IGFBP-4 and NT-IGFBP-4 levels were determined by specific, novel immunoassays, and PAPP-A and IGF-I by commercial immunoassays.<br />Results: Plasma PAPP-A was strongly elevated upon STEMI, UFH-administration and PCI with mean concentrations (95%-confidence interval) pre-PCI, post-PCI, day 1, and day 2 of 13.0 (11.2;15.2), 14.8 (13.1;16.8), 1.03 (0.90;1.18), and 1.08 (0.92;1.28) μg/L, respectively (p<0.0001). Pre-PCI concentrations of IGFBP-4, CT-IGFBP-4 and NT-IGFBP-4 were 154 (142;166), 53 (47;60) and 136 (122;150) μg/L, and levels were unaltered post-PCI. Concentrations increased on day 1 by 63 (43;87)%, 69 (36;110)%, and 47 (21;79)%, respectively (p<0.0001), i.e. at a time point when PAPP-A levels had normalized.<br />Conclusion: Plasma IGFBP-4-fragment levels are not acutely altered in patients with STEMI treated with UFH and PCI. Thus, they possess potentials as prognostic markers in ACS patients.<br /> (Copyright © 2014 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Aged
Anticoagulants therapeutic use
Biomarkers blood
Female
Humans
Male
Middle Aged
Myocardial Infarction diagnosis
Prospective Studies
Treatment Outcome
Heparin therapeutic use
Insulin-Like Growth Factor Binding Protein 4 blood
Myocardial Infarction blood
Myocardial Infarction therapy
Percutaneous Coronary Intervention trends
Pregnancy-Associated Plasma Protein-A metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1873-2933
- Volume :
- 48
- Issue :
- 4-5
- Database :
- MEDLINE
- Journal :
- Clinical biochemistry
- Publication Type :
- Academic Journal
- Accession number :
- 25489725
- Full Text :
- https://doi.org/10.1016/j.clinbiochem.2014.11.022